HZHao Zhang

Hao Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hao Zhang has a total of 103 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correction: MYCBP2-mediated HNF4α ubiquitination reprogrammed lipid metabolism in MASH-associated hepatocellular carcinoma

    by Hao Zhang, Xiangxu Kong, Haoran Qu, Yi Gao, Zhengyao Guan, Huaxin Zhou, Zhaoqing Yin, Kangping Lu, Wei Wang, Xiangyu Zhai, et al.

  • MYCBP2-mediated HNF4α ubiquitination reprogrammed lipid metabolism in MASH-associated hepatocellular carcinoma

    by Hao Zhang, Xiangxu Kong, Haoran Qu, Yi Gao, Zhengyao Guan, Huaxin Zhou, Zhaoqing Yin, Kangping Lu, Wei Wang, Xiangyu Zhai, et al.

    Hepatocellular carcinoma (HCC) is a major global health burden, with metabolic dysfunction-associated steatohepatitis (MASH) emerging as a significant risk factor. The scarcity of effective pharmacological treatments for MASH and its progression to HCC underscores the need for deeper molecular insights. Our study identifies Myc-binding protein 2 (MYCBP2), an E3 ubiquitin ligase, as a potential tumor suppressor in MASH-related HCC. Through transcriptomic and proteomic analyses, we observed significant downregulation of MYCBP2 in HCC tissues. In vitro and in vivo experiments demonstrate that MYCBP2 inhibits HCC cell proliferation, migration, and invasion by modulating lipid metabolism pathways. Mechanistically, MYCBP2 promotes the ubiquitination and degradation of Hepatocyte Nuclear Factor 4 Alpha (HNF4α). This ubiquitination occurs via K33- and K48-linked polyubiquitin chains at lysines 300 and 307 of HNF4α. The results showed that MYCBP2 influences the expression of lipid metabolism-related genes and attenuates HNF4α's regulatory role in lipid metabolism through the mediated ubiquitination and degradation of HNF4α. Our findings elucidate the MYCBP2-HNF4α axis as a novel regulatory pathway in MASH-related HCC and highlight the broader implications of ubiquitination in cancer metabolism, offering a promising metabolic target for therapeutic intervention.


  • Open Access

    LRP1B suppresses HCC progression through the NCSTN/PI3K/AKT signaling axis and affects doxorubicin resistance

    by Xiangyu Zhai, Zhijia Xia, Gang Du, Xinlu Zhang, Tong Xia, Delin Ma, Xiaosong Li, Bin Jin, Hao Zhang

    Accumulating evidence supports the association of somatic mutations with tumor occurrence and development. We aimed to identify somatic mutations with important implications in hepatocellular carcinoma (HCC) and explore their possible mechanisms. The gene mutation profiles of HCC patients were assessed, and the tumor mutation burden was calculated. Gene mutations closely associated with tumor mutation burden and patient overall survival were identified. In vivo and in vitro experiments were performed to verify the effects of putative genes on proliferation, invasion, drug resistance, and other malignant biological behaviors of tumor cells. Fourteen genes with a high mutation frequency were identified. The mutation status of 12 of these genes was closely related to the mutation burden. Among these 12 genes, LRP1B mutation was closely associated with patient prognosis. Nine genes were associated with immune cell infiltration. The results of in vivo and in vitro experiments showed that the knockdown of LRP1B promotes tumor cell proliferation and migration and enhances the resistance of tumor cells to liposomal doxorubicin. LRP1B could directly bind to NCSTN and affect its protein expression level, thereby regulating the PI3K/AKT pathway. Our mutational analysis revealed complex and orchestrated liposomal alterations linked to doxorubicin resistance that may also render cancers less susceptible to immunotherapy and also provides new treatment alternatives.


  • Rapid Intracellular Detection and Analysis of Lipid Droplets’ Morpho-Chemical Composition by Phase-Guided Raman Sampling

    by Hao Zhang, Jingde Fang, Yichuan Dai, Yang Pan, Kaiqin Chu, Zachary J. Smith

    Intracellular lipid droplets (LDs) are dynamic, complex organelles involved in nearly all aspects of cellular metabolism. In situ characterization methods are primarily limited to fluorescence imaging, which yields limited chemical information, or Raman spectroscopy, which provides excellent chemical profiling but very low throughput. Here, we propose a new paradigm where locations of both large and small droplets are obtained automatically from high-resolution phase images and fed into a galvomirror-controlled Raman sampling arm to obtain the full spectrum of each LD efficiently. Using this phase-guided Raman sampling, we can characterize hundreds of LDs within a single cell in minutes and easily acquire more than 40,000 high-quality spectra. The data set revealed strong, cell line-dependent, cell-dependent, and individual droplet-dependent composition changes to various culture conditions. In particular, we revealed a strong competitive relationship between mono- and polyunsaturated fatty acids, where supplementation with one led to a relative decrease in the other.


  • Open Access

    Supplementary Data from Identification and Characterization of Synthetic Viability with ERCC1 Deficiency in Response to Interstrand Crosslinks in Lung Cancer

    by Joshua R. Heyza, Wen Lei, Donovan Watza, Hao Zhang, Wei Chen, Jessica B. Back, Ann G. Schwartz, Gerold Bepler, Steve M. Patrick

    Supplemental Figure S1. A. Clonogenic survival assays with cisplatin treatment in p53WT cell lines {plus minus} ERCC1. B. Clonogenic survival assays with cisplatin treatment in p53 null and p53mutant cell lines {plus minus} ERCC1. n = 3 independent experiments plated in triplicate for each cell line. Data plotted as average of at least three independent experiments {plus minus}SD. C. Viability assays with cisplatin treatment in p53WT cell lines {plus minus} ERCC1. D. Viability assays with cisplatin treatment in p53null and p53mutant cell lines {plus minus} ERCC1. n = 3 independent experiments plated in triplicate for each cell line. Data plotted as average of at least three independent experiments {plus minus} SD. Supplemental Figure S2. A. Cell lines utilized in the current study and status of p53, EGFR, and K-ras are listed. Mutation status was obtained from Cosmic Database (cancer.sanger.ac.uk) or cBIOportal (cbioportal.org) (except for H522 p53 status where Sanger sequencing did not identify the homozygous deletion that was previously reported. B. Western blot of additional ERCC1D clones in H460 and H1299 cells and the XPFD H1299 cells. Additional ERCC1D clones in this figure were validated by western blot and the XPFD clone was validated by sequencing. C-F. Colony survival assays of additional ERCC1D and XPFD clones. G-H. Western blot showing re-expression of ERCC1-202 in H460 and H1299 ERCC1D cells. Colony survival assay shows increased resistance to cisplatin with re-expression of ERCC1-202. n=3, plated in triplicate for each colony assay performed in this figure. Error bars represent SD of the averages of all experiments. Supplemental Figure S3. A. Clonogenic survival assays with MMC treatment in p53WT cell lines {plus minus} ERCC1. B. Clonogenic survival assays with MMC treatment in p53null and p53mutant cell lines {plus minus} ERCC1. n=2, in triplicate for all colony survival assays with MMC treatment. Error bars represent SD. C. Clonogenic survival assays of H460 and H1299 WT and ERCC1? cells with camptothecin treatment. n=3, in triplicate. Error bars represent {plus minus} SD. D. UV-C sensitivity assays in H460 and H1299 WT and ERCC1??cells. n=2, in triplicate. Error bars represent {plus minus} SD. Supplemental Figure S4. A. Sensitivity of parental and ERCC1? cells to etoposide treatment in colony survival assays. n=2, plated in triplicate for each cell line. Error bars represent {plus minus} SD. B. Sensitivity of parental and ERCC1? cells to gemcitabine treatment in colony survival assays. n=2, plated in triplicate for each cell line. Error bars represent {plus minus} SD. Supplemental Figure S5. A. p53 re-expression/disruption by CRISPR-Cas9 in H1299, H460, and H522 cells. B. Clonogenic assay of H460 ERCC1? and ERCC1?/p53* cells fixed at Day 6 and Day 12. C. p53 disruption by CRISPR-Cas9 in A549 cells. D. Clonogenic survival of A549 isogenic cells after treatment with cisplatin. n=3, plated in triplicate for each cell line. Error bars represent {plus minus} SD. E. Sequencing results of p53 editing in H460, H522, and A549 cells. F. Validation of ERCC1? in OV2008 and *C13 cells by western blot. G. Induction of p53 after cisplatin treatment. H. Clonogenic survival of OV2008 and *C13 cells after cisplatin treatment. n=2, plated in triplicate for each cell line. Error bars represent {plus minus} SD. Supplemental Figure S6. A. Western blot validation of XPA knockout by CRISPR-Cas9. Colony survival assay of H1299 WT, ERCC1D, XPFD, and XPAD after B. cisplatin and C. MMC treatment. D. Validation of second XPAD clone by western blot. E. Colony survival assay of H1299 WT and second XPAD clone with cisplatin treatment. Supplemental Figure S7. Top: Progression Free Survival of Stage 3+4 ovarian cancer patients stratified by p53 status and ERCC1 expression who received a platinum agent. Bottom: Overall Survival of Stage 3+4 ovarian cancer patients stratified by p53 status and ERCC1 expression who received a platinum agent. Data obtained the 2017 TCGA Ovarian Cancer Data Set from kmplot.com/ovca. Supplemental Table S1: shRNA, primers, crRNAs Supplemental Table S2: Antibodies

  • Open Access

    Supplementary Data from Identification and Characterization of Synthetic Viability with ERCC1 Deficiency in Response to Interstrand Crosslinks in Lung Cancer

    by Joshua R. Heyza, Wen Lei, Donovan Watza, Hao Zhang, Wei Chen, Jessica B. Back, Ann G. Schwartz, Gerold Bepler, Steve M. Patrick

    Supplemental Figure S1. A. Clonogenic survival assays with cisplatin treatment in p53WT cell lines {plus minus} ERCC1. B. Clonogenic survival assays with cisplatin treatment in p53 null and p53mutant cell lines {plus minus} ERCC1. n = 3 independent experiments plated in triplicate for each cell line. Data plotted as average of at least three independent experiments {plus minus}SD. C. Viability assays with cisplatin treatment in p53WT cell lines {plus minus} ERCC1. D. Viability assays with cisplatin treatment in p53null and p53mutant cell lines {plus minus} ERCC1. n = 3 independent experiments plated in triplicate for each cell line. Data plotted as average of at least three independent experiments {plus minus} SD. Supplemental Figure S2. A. Cell lines utilized in the current study and status of p53, EGFR, and K-ras are listed. Mutation status was obtained from Cosmic Database (cancer.sanger.ac.uk) or cBIOportal (cbioportal.org) (except for H522 p53 status where Sanger sequencing did not identify the homozygous deletion that was previously reported. B. Western blot of additional ERCC1D clones in H460 and H1299 cells and the XPFD H1299 cells. Additional ERCC1D clones in this figure were validated by western blot and the XPFD clone was validated by sequencing. C-F. Colony survival assays of additional ERCC1D and XPFD clones. G-H. Western blot showing re-expression of ERCC1-202 in H460 and H1299 ERCC1D cells. Colony survival assay shows increased resistance to cisplatin with re-expression of ERCC1-202. n=3, plated in triplicate for each colony assay performed in this figure. Error bars represent SD of the averages of all experiments. Supplemental Figure S3. A. Clonogenic survival assays with MMC treatment in p53WT cell lines {plus minus} ERCC1. B. Clonogenic survival assays with MMC treatment in p53null and p53mutant cell lines {plus minus} ERCC1. n=2, in triplicate for all colony survival assays with MMC treatment. Error bars represent SD. C. Clonogenic survival assays of H460 and H1299 WT and ERCC1? cells with camptothecin treatment. n=3, in triplicate. Error bars represent {plus minus} SD. D. UV-C sensitivity assays in H460 and H1299 WT and ERCC1??cells. n=2, in triplicate. Error bars represent {plus minus} SD. Supplemental Figure S4. A. Sensitivity of parental and ERCC1? cells to etoposide treatment in colony survival assays. n=2, plated in triplicate for each cell line. Error bars represent {plus minus} SD. B. Sensitivity of parental and ERCC1? cells to gemcitabine treatment in colony survival assays. n=2, plated in triplicate for each cell line. Error bars represent {plus minus} SD. Supplemental Figure S5. A. p53 re-expression/disruption by CRISPR-Cas9 in H1299, H460, and H522 cells. B. Clonogenic assay of H460 ERCC1? and ERCC1?/p53* cells fixed at Day 6 and Day 12. C. p53 disruption by CRISPR-Cas9 in A549 cells. D. Clonogenic survival of A549 isogenic cells after treatment with cisplatin. n=3, plated in triplicate for each cell line. Error bars represent {plus minus} SD. E. Sequencing results of p53 editing in H460, H522, and A549 cells. F. Validation of ERCC1? in OV2008 and *C13 cells by western blot. G. Induction of p53 after cisplatin treatment. H. Clonogenic survival of OV2008 and *C13 cells after cisplatin treatment. n=2, plated in triplicate for each cell line. Error bars represent {plus minus} SD. Supplemental Figure S6. A. Western blot validation of XPA knockout by CRISPR-Cas9. Colony survival assay of H1299 WT, ERCC1D, XPFD, and XPAD after B. cisplatin and C. MMC treatment. D. Validation of second XPAD clone by western blot. E. Colony survival assay of H1299 WT and second XPAD clone with cisplatin treatment. Supplemental Figure S7. Top: Progression Free Survival of Stage 3+4 ovarian cancer patients stratified by p53 status and ERCC1 expression who received a platinum agent. Bottom: Overall Survival of Stage 3+4 ovarian cancer patients stratified by p53 status and ERCC1 expression who received a platinum agent. Data obtained the 2017 TCGA Ovarian Cancer Data Set from kmplot.com/ovca. Supplemental Table S1: shRNA, primers, crRNAs Supplemental Table S2: Antibodies

  • TGF-β1/Smad3 upregulates UCA1 to promote liver fibrosis through DKK1 and miR18a

    by Zhangshuo Yang, Hao Zhang, Maohui Yin, Zhixiang Cheng, Ping Jiang, Maohui Feng, Zhisu Liu, Bo Liao

    TGF‐β1 is the strongest cytokine known to promote liver fibrosis. It has been previously demonstrated that the activation of TGF‐β1 i


  • Open Access

    Estimating the transmissibility of hepatitis C: A modelling study in Yichang City, China

    by Yao Wang, Zeyu Zhao, Hao Zhang, Qin Lin, Ning Wang, Mikah Ngwanguong Hannah, Jia Rui, Tianlong Yang, Peihua Li, Siying Mao, et al.

    Yichang is a city in central China in the Hubei Province. This study aimed to estimate the dynamics of the transmissibility of hepatitis C using a mathematical model and predict the transmissibility of hepatitis C in 2030. Data of hepatitis C cases from 13 counties or districts (cities) in Yichang from 2008 to 2016 were collected. A Susceptible-Infectious-Chronic-Recovered (SICR) model was developed to fit the data. The transmissibility of hepatitis C at the counties or districts was calculated based on new infections (including infected or chronically infected cases) reported monthly in the city caused by one infectious individual (MNI). The trend of the MNI was fitted and predicted using 11 models, with the coefficient of determination (R2) was being used to test the goodness of fit of these models. A total of 3065 cases of hepatitis C were reported in Yichang from 2008 to 2016. The median MNI of Yichang was 0.0768. According to the fitting results and analysis, the trend of transmissibility of hepatitis C in Yichang City conforms with the Logarithmic (R2 = 0.918, P < 0.001):MNI = 0.265 – 0.108log(t), and Exponential (R2 = 0.939, P < 0.001):MNI = 0.344е(-0.278t) models. Hence, the transmission of hepatitis C virus at the county level has a downward trend. In conclusion, the transmissibility of hepatitis C in Yichang has a downward trend. With the current preventive and control measures in place, the spread of hepatitis C can be controlled.


  • Open Access

    Development and Validation of an RNA Binding Protein-associated Prognostic Model for Hepatocellular Carcinoma

    by Hao Zhang, Peng Xia, Weijie Ma, Yufeng Yuan

    The survival rate of patients with hepatocellular carcinoma is variable. The abnormal expression of RNA-binding proteins (RBPs) is closely related to the occurrence and development of malignant tumors. The primary aim of this study was to identify RBPs related to the prognosis of liver cancer and to construct a prognostic model of liver cancer.


  • Irreversible epidermal growth factor receptor inhibitor Z25h exhibits pronounced inhibition on non-small cell lung adenocarcinoma cell line Hcc827

    by Jin Wang, Shuai Tan, Ping-Ping Yan, Xue Xiao, Hao Zhang, San-Qi Zhang, Wei Li, Yong-Xiao Cao, Hong-Ying Wang

    The epidermal growth factor receptor (EGFR) signaling is frequently activated in lung cancer. In our previous study, a new class of compounds containing pyrido[3,4-d]pyrimidine scaffold with an acrylamide moiety was designed as irreversible EGFR-tyrosine kinase inhibitors to overcome acquired EGFR-T790M resistance. In this study, we selected the most promising compound Z25h to further investigate its effects and the underlying mechanism against non-small cell lung adenocarcinoma cells in vitro. Four different non-small cell lung adenocarcinoma cell lines were selected to test the antiviability profile of Z25h, and Hcc827 was the most sensitive to the drug treatment. Z25h caused cell cycle arrest at G0-G1 phase, and triggered strong early apoptosis in Hcc827 cells at 0.1 μM and late apoptosis in A549, H1975 and H1299 cells at 10 μM by 48 h treatment. Z25h inhibited the activation of EGFR and its downstream PI3K/AKT/mTOR pathway in the four tested cell lines, leading to the inhibition of cellular biosynthetic and metabolic processes and the promotion of apoptotic process. However, the effect of Z25h on mitogen-activated protein kinase pathway varies from cell lines. In addition, Z25h sensitized H1975 cells to X-ray radiation, and it also enhanced the radiation effect on A549 cells, while no obvious effect of Z25h was observed on the cell viability inhibition of H1299 cells induced by radiation. Hereby, Z25h might be considered as a potential therapeutic drug candidate for non-small cell lung adenocarcinoma treatment.